Join our daily newsletter At The Bell to receive exclusive market insights
- Rhythm Biosciences (RHY) completes recruitment for its clinical trial for detecting colorectal cancer
- The company has recruited 815 patients for its clinical trial for ColoSTAT, a low-cost, simple blood test for the early detection of colorectal cancer, aimed at mass-market screening
- Blood sample collection can now begin to finalise and lock in the patient database, and other routine works
- The final study report for this trial is targeted for completion in the first half of 2022 and is a key component for TGA registration
- Rhythm Biosciences is trading in the grey at $1.18 at 11:28 am AEST
Rhythm Biosciences (RHY) has rounded off recruitment for its clinical trial for detecting colorectal cancer.
The company has enlisted 815 patients for its clinical trial for ColoSTAT, a low-cost, simple blood test for the early detection of colorectal cancer, which is aimed at mass-market screening.
The patients span across 11 clinical trial sites Australia wide. Blood sample collection can now begin to finalise and lock in the patient database, and other routine works.
“With the recruitment target now met for the ColoSTAT clinical trial, the company remains fully focused on working with our partners to progress through the remaining phases for trial completion,” Rhythm CEO, Glenn Gilbert said.
Rhythm said it will continue to work with clinical research organisation, Accelagen, and its analytical testing partner, Sonic Clinical Trials, to progress the next stages in finalising the trial, before completing the final clinical study report.
The final study report for this trial is targeted for completion in the first half of 2022 and is a key component for the TGA registration package.
Meanwhile, Rhythm said CE Mark certification for Europe was independent of this clinical trial activity was being completed, but believed filing was still on track for late 2021.
Rhythm Biosciences was trading in the grey at $1.18 at 11:28 am AEST.
